跳至主要内容
临床试验/NCT00436527
NCT00436527已完成4 期

MetroGel 1% Hydration Study: A Kinetic Regression Study

Galderma R&D1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2006年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Galderma R&D
入组人数
26
试验地点
1
主要终点
Six replicate Corneometer CM 825 measurements

研究概览

简要总结

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

详细描述

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application as measured by the Corneometer CM 825.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions

排除标准

  • Individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis

研究组 & 干预措施

1

Other

干预措施: Metronidazole gel 1% (Drug)

结局指标

主要结局

Six replicate Corneometer CM 825 measurements

时间窗: 8 hours

次要结局

  • Adverse events(1 day)

研究者

发起方
Galderma R&D
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验